Hawiger still blazing a trail in inflammation research

Nov. 10, 2022—Vanderbilt research describes a new investigational peptide drug that can penetrate immune and nonimmune cells, and block inflammatory signaling in a preclinical model of atopic dermatitis — eczema.

Read more